Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue

February 15, 2019
The pediatric cancer treatment Erwinase (crisantaspase), which was developed by Ohara Pharmaceutical at the request of a health ministry panel, still remains unlisted and unlaunched in Japan despite being approved in December 2016. Just after Erwinase was approved, a GMP...read more